射血分数降低心衰患者药物治疗的滴定现状:CHAMP-HF注册研究
该研究基于美国CHAMP-HF注册中2588例无禁忌证的慢性HFrEF门诊患者,评估基线及12个月时ACEI/ARB、ARNI、β受体阻滞剂和MRA的使用与剂量。结果显示多数患者未达到靶剂量,12个月内启动或加量的比例低,同时达到三类药物靶剂量者不足1%。
要点
- 美国HFrEF门诊患者中多数未达指南推荐药物靶剂量。
- 12个月内药物启动或加量比例低,多数患者治疗无调整。
- 同时达到ACEI/ARB/ARNI、β受体阻滞剂和MRA靶剂量者不足1%。
核心结论
- 当代美国HFrEF注册研究中,多数合格患者随访期间未接受靶剂量药物治疗,且极少患者剂量上调。
研究设计与样本
- 基于美国CHAMP-HF注册的2588例慢性HFrEF门诊患者,具有完整药物数据且无禁忌证,评估基线及12个月随访时四类药物的使用与剂量。
主要发现
- 基线时MRA、β受体阻滞剂、ACEI/ARB和ARNI达到靶剂量的患者比例分别为25%、20%、11%和2%。
- 12个月时MRA、β受体阻滞剂、ACEI/ARB和ARNI启动或加量的比例分别为6%、10%、7%和10%。
- 12个月时上述四类药停药或减量的比例分别为4%、7%、11%和3%。
- 12个月内同时接受ACEI/ARB/ARNI、β受体阻滞剂和MRA靶剂量的患者不足1%。
- 多因素分析显示既往心衰住院、较高血压、较低射血分数与启动或加量相关,既往心衰住院、生活质量受损、更差功能分级与停药或减量相关。
临床怎么用
- 临床实践中应主动评估并上调HFrEF指南导向药物至靶剂量,尤其关注未调整治疗的患者。
- 对既往心衰住院、低射血分数、高血压等患者可考虑优先滴定,同时警惕功能分级差和生活质量受损者的减量风险。
局限性
- 原文未报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Guidelines recommend that patients with heart failure with reduced ejection fraction (HFrEF) have medical therapy titrated to target doses derived from clinical trials, as tolerated. The degree to which titration occurs in contemporary U.S. practice is unknown. OBJECTIVES: This study sought to characterize longitudinal titration of HFrEF medical therapy in clinical practice and to identify associated factors and reasons for medication changes. METHODS: Among 2,588 U.S. outpatients with chronic HFrEF in the CHAMP-HF (Change the Management of Patients with Heart Failure) registry with complete medication data and no contraindications to medical therapy, use and dose of angiotensin-converting enzyme inhibitor (ACEI)/angiotensin II receptor blocker (ARB), angiotensin receptor-neprilysin inhibitor (ARNI), beta-blocker, and mineralocorticoid receptor antagonist (MRA) were examined at baseline and at 12-month follow-up. RESULTS: At baseline, 658 (25%), 525 (20%), 287 (11%), and 45 (2%) patients were receiving target doses of MRA, beta-blocker, ACEI/ARB, and ARNI therapy, respectively. At 12 months, proportions of patients with medication initiation or dose increase were 6% for MRA, 10% for beta-blocker, 7% for ACEI/ARB, and 10% for ARNI; corresponding proportions with discontinuation or dose decrease were 4%, 7%, 11%, and 3%, respectively. Over 12 months, <1% of patients were simultaneously treated with target doses of ACEI/ARB/ARNI, beta-blocker, and MRA. In multivariate analysis, across the classes of medications, multiple patient characteristics were associated with a higher likelihood of initiation or dose increase (e.g., previous HF hospitalization, higher blood pressure, lower ejection fraction) and discontinuation or dose decrease (e.g., previous HF hospitalization, impaired quality of life, more severe functional class). Medical reasons were the most common reasons for discontinuations and dose decreases of each therapy, but the relative contributions from patient preference, health team, and systems-based reasons varied by medication. CONCLUSIONS: In this contemporary U.S. registry, most eligible HFrEF patients did not receive target doses of medical therapy at any point during follow-up, and few patients had doses increased over time. Although most patients had no alterations in medical therapy, multiple clinical factors were independently associated with medication changes. Further quality improvement efforts are urgently needed to improve guideline-directed medication titration for HFrEF.
引用
- Greene SJ, Fonarow GC, DeVore AD, et al. Titration of Medical Therapy for Heart Failure With Reduced Ejection Fraction. J Am Coll Cardiol. 2019. PMID: 30844480. doi:10.1016/j.jacc.2019.02.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。